Related Experiment Video

Updated: Jul 16, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

The gap between effect of drugs and effectiveness of treatments

Per Soelberg Sorensen1

  • 1Copenhagen Multiple Sclerosis Research Center, Department of Neurology 2082, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. pss@rh.dk

Journal of the Neurological Sciences
|March 17, 2007
PubMed

Insights

Current multiple sclerosis (MS) therapies offer moderate effectiveness, with newer drugs targeting inflammation but not disease progression. Future treatments may require combination therapies with neuroprotective properties for better outcomes.

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Clinical Neurology

Background:

  • Multiple sclerosis (MS) treatments like interferon-beta and glatiramer acetate show limited effectiveness, reducing relapse rates by only 30% and impacting disease progression minimally.
  • Newer targeted immunotherapies, such as campath-1H and natalizumab, demonstrate significant efficacy against inflammation-related MS symptoms like relapses and MRI activity.
  • However, these advanced therapies have yet to prove their impact on the long-term progression of multiple sclerosis.

Purpose of the Study:

  • To analyze the gap between the pharmacological effects of existing MS drugs and their overall treatment effectiveness.
  • To identify the limitations of current therapeutic strategies in addressing both inflammation and neurodegeneration in MS.
  • To propose future directions for MS drug development, emphasizing the need for comprehensive therapeutic approaches.

Main Methods:

  • Review and synthesis of existing clinical trial data and pharmacological studies on MS therapies.
  • Comparative analysis of the efficacy of approved MS drugs (interferon-beta, glatiramer acetate) versus newer targeted immunotherapies (campath-1H, natalizumab).
  • Evaluation of the mechanisms of action of these drugs in relation to immune system modulation and disease progression in MS.

Main Results:

  • Approved MS drugs provide moderate control over relapses but fail to halt disease progression.
  • Targeted immunotherapies are highly effective against inflammatory MS manifestations but their long-term effect on progression remains undetermined.
  • A significant gap exists between the observed drug effects and the desired treatment effectiveness in managing MS.

Conclusions:

  • Current MS therapies are insufficient to fully address the complexities of the disease, particularly long-term progression.
  • The development of novel MS drugs should focus on achieving both potent anti-inflammatory and essential neuroprotective effects.
  • Combination therapies, utilizing drugs with diverse mechanisms of action, may be necessary to effectively manage multiple sclerosis and improve patient outcomes.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...